Gujarat High Court Rejects MSME's SARFAESI Challenge, Says RBI Revival Benefits Must Be Sought Early
The Gujarat High Court on 3 November rejected a writ petition filed by Pharmakem challenging the Punjab and Sind Bank's SARFAESI proceedings, holding that an MSME must seek the benefit of the RBI Framework when replying to a demand notice under Section 13(2) of the SARFAESI Act, 2002.
Justice Nikhil S. Kariel further observed that an MSME cannot seek the benefit of the RBI's Framework for Revival and Rehabilitation of Micro, Small and Medium Enterprises at a belated stage after allowing proceedings under the SARFAESI Act to progress. The Bench said:
“Considering from the perspective of the law laid down by the Hon'ble Apex Court, it would appear that the benefit of the Framework has to be sought for by the MSME in reply to the notice under Section 13(2) of the Act. In the instant case, while the reply portrays as if it is to the notice under Section 13(2) of the Act, yet, it would appear that the petitioner had permitted the proceedings under the Act to continue for a while…,”
Pharmakem approached the High Court challenging a sale notice dated 29 September 2026 issued by Punjab and Sind Bank under the SARFAESI Act, for recovery of its dues through the sale of the secured property.
It contended that the Bank was obligated to comply with the RBI Framework for Revival and Rehabilitation of MSMEs, which requires banks to identify incipient stress, evaluate remedial measures and adopt appropriate measures before classifying an MSME account as a Non-Performing Asset (NPA).
The Bank opposed the petition, contending that the MSME had neither invoked the Framework when it received the demand notice under Section 13(2) of the SARFAESI Act nor replied to the notice. It further submitted that Pharmakem raised its MSME-related grievance for the first time after the Bank had taken symbolic possession of the secured property under Section 13(4) of the Act.
The Court held that an MSME seeking the benefit of the Framework must raise its claim in response to the demand notice under Section 13(2) of the SARFAESI Act. It observed that Pharmakem was required to substantiate its MSME status by producing relevant documents before the Bank and other concerned authorities at the appropriate stage.
It relied on the Supreme Court's judgment in Shri Swami Samarth Construction & Finance Solution Pvt. Ltd. v. The Board of Directors of NKGSB Co-operative Bank Ltd. & Anr., which held that Courts must balance the legitimate interests of banks in recovering their dues against the interests of MSMEs. The Supreme Court had also cautioned against allowing MSMEs to misuse legal proceedings to obstruct banks from enforcing their security under the SARFAESI Act.
Further, the Bench noted that Pharmakem had allowed the SARFAESI proceedings to continue until the Bank took symbolic possession of the secured property. It therefore held that Pharmakem could not claim the benefit of the RBI Framework at that belated stage.
Accordingly, the High Court rejected the writ petition. However, it clarified that Pharmakem would remain entitled to pursue remedies available under the SARFAESI Act to challenge measures taken under Sections 13(4) or 14 of the Act, as applicable.
For Petitioner: N.R. Parikh
For Respondent No. 1 (Bank): Mohitkumar R. Gupta
For Respondent No. 2: Rituraj J. Meena
For Respondent No. 3: Mittal Gadhvi and Ankit Shah